NTHM's Rulebook Cut Tech and Bought Pipelines. The Product Is the Rulebook.

The NBI Thematic Rotation ETF came out of its latest rebalance holding a portfolio that shares little with the one it carried in, technology sliding from 40.78% of the fund to 25.20% as energy climbed from 10.70% to 25.17% and healthcare went from 0.08% to 15.42%, the moves of the Thematic Rotation Quality Momentum Screened Index, which NTHM tracks, made by a screening rule rather than by anyone's judgment about pipelines or weight-loss drugs. The holder's part in the transaction was to stay invested while it happened.

What the screen chose is easy to read: midstream operators — ONEOK, Williams Companies and Kinder Morgan among the new positions — account for most of the energy sleeve, while healthcare's added weight sits on metabolic-drug makers and the GLP-1 weight-loss market, with Eli Lilly and Novo Nordisk both entering the top ten. Industrial goods fell from 16.79% to 5.68% and basic materials from 23.07% to 16.01% to fund the shift, while KLA and Palantir slid down the rankings on their way out of favor.

The exits carry the same signature: Bloom Energy, KLA, Showa Denko and Albemarle left the top ten, replaced by pipeline and pharmaceutical names alongside standing positions in Meta Platforms, Microsoft and Tencent, while U.S. exposure dropped from 50.17% to 43.04% and Canadian holdings rose to 7.87%, a change that reads as a byproduct of buying North American midstream rather than a country call. A screen follows a price record, not a view, which is why the two sleeves that gained share — gas infrastructure and metabolic drugs — share little beyond the momentum that admitted them.

Nothing in the rebalance required a holder's consent, and as this publication noted when HALX, QGRO, VFLO and OUSM rotated out of AI exposure their investors never voted to sell, the rulebook is not a view the buyer endorses but a timing mechanism the buyer rents. NTHM's name describes that machinery honestly and its current exposure not at all.

The fund now spreads across seven themes at roughly 12.5% to 16% each, its top ten lighter than before — balance produced by a rebalance rather than chosen. The next review is the one to watch: a screen that admitted Eli Lilly and Novo Nordisk on momentum is free to drop them on momentum, and our archive's note that THNR's return still rides on Eli Lilly is the caution that a longer holdings list is not the same thing as a smaller bet.